Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deals

Set Alert for Deals

Canada’s Apotex Is Snapped Up By SK Capital

Apotex is to be acquired by SK Capital, the private investment firm has announced. The Canadian generics giant’s new owner has promised to invest in the firm to “support Apotex’s next phase of growth and continued innovation for patient affordability.”

Deals M & A

Aspen Hunts For Licensing Opportunities After Intense Consolidation

Aspen Pharmacare is looking to build and augment where it has laid down foundations, after reshaping its operations with numerous significant divestments.

Strategy Sales & Earnings

MPP Teams Up With MedinCell For Investigational Malaria Transmission Treatment

The Medicines Patent Pool has secured a licensing deal with MedinCell for a long-acting injectable ivermectin drug formulation which could be used to prevent ongoing spread of malaria.

Deals Intellectual Property

Hikma And Adalvo Ally On Nasal Spray For MENA

Hikma and Adalvo have struck a licensing deal that will see Hikma commercialize a “high value” nasal spray treatment for allergic rhinitis in the MENA region.

Deals Middle East and Africa

Upsher-Smith Shuffles Portfolio With A Pair Of Deals

Sawai’s Upsher-Smith business in the US has announced a pair of deals that will see the firm expand an existing partnership with Appco for a “near-term generic product opportunity” as well as divesting two “dormant” ANDAs in favor of a focus on more immediate assets.

Deals Strategy

Bora Bulks Up With Move For Taiwan’s TWi

Bora Pharmaceuticals says it has become “the largest pharmaceutical group by volume in Taiwan” after acquiring TWi Pharmaceuticals.

Deals M & A

Lupin And DKSH To Market Five Alvotech Biosimilars In The Philippines

Lupin’s Multicare Pharmaceuticals subsidiary in the Philippines will partner with distributor DKSH to market five Alvotech biosimilars. Alvotech’s biosimilars, which remain at the pre-approval stages, reference Prolia/Xgeva, Eylea, Simponi, and two more undisclosed molecules. 

Deals Biosimilars

Lupin Liquidating Japan JV With Yoshindo, Partners With I’Rom For Denosumab Biosimilar

Lupin is liquidating its share in a Japanese biosimilar joint venture with Yoshindo, leading the Indian firm to tie-up with familiar face I’Rom Group to develop and commercialize a biosimilar to Amgen’s Prolia/Xgeva (denosumab) in Japan’s $500m addressable market. Meanwhile, Lupin has also received UK approval for generic Spiriva.

Strategy Deals

Sandoz Set To Become Public Company In 2023 As Novartis Confirms Spin-Off

Following years of dedicated moves towards greater autonomy for Sandoz, the generics and biosimilars giant is to become a publicly traded, standalone firm via a 100% spin-off from parent Novartis. However, a substantial offer could still derail plans.

Deals M & A
See All
UsernamePublicRestriction

Register